441 related articles for article (PubMed ID: 18447661)
21. The absence of synergism between the effects of an aldose reductase inhibitor, epalrestat, and a vasodilator, cilostazol, on the nerve conduction slowing and the myelinated fiber atrophy in streptozotocin-induced diabetic rats.
Sasaki H; Naka K; Kishi Y; Furuta M; Sanke T; Mukoyama M; Nanjo K
Exp Neurol; 1997 Aug; 146(2):466-70. PubMed ID: 9270057
[TBL] [Abstract][Full Text] [Related]
22. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
He J; Gao HX; Yang N; Zhu XD; Sun RB; Xie Y; Zeng CH; Zhang JW; Wang JK; Ding F; Aa JY; Wang GJ
Acta Pharmacol Sin; 2019 Jan; 40(1):86-97. PubMed ID: 29930278
[TBL] [Abstract][Full Text] [Related]
23. Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis.
Okamoto H; Nomura M; Nakaya Y; Uehara K; Saito K; Kimura M; Chikamori K; Ito S
Intern Med; 2003 Aug; 42(8):655-64. PubMed ID: 12924487
[TBL] [Abstract][Full Text] [Related]
24. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
Hamada Y; Nakamura J; Naruse K; Komori T; Kato K; Kasuya Y; Nagai R; Horiuchi S; Hotta N
Diabetes Care; 2000 Oct; 23(10):1539-44. PubMed ID: 11023149
[TBL] [Abstract][Full Text] [Related]
25. A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration.
Nicolucci A; Carinci F; Cavaliere D; Scorpiglione N; Belfiglio M; Labbrozzi D; Mari E; Benedetti MM; Tognoni G; Liberati A
Diabet Med; 1996 Dec; 13(12):1017-26. PubMed ID: 8973882
[TBL] [Abstract][Full Text] [Related]
26. Three-year inhibition of aldose reductase on development of symptomatic neuropathy in diabetic patients.
Baba M; Kimura K; Suda T; Yagihashi S;
J Peripher Nerv Syst; 2006 Jun; 11(2):176-8. PubMed ID: 16787519
[No Abstract] [Full Text] [Related]
27. Effect of an aldose reductase inhibitor on esophageal dysfunction in diabetic patients.
Kinekawa F; Kubo F; Matsuda K; Fujita Y; Kobayashi M; Funakoshi F; Uchida N; Watanabe S; Tomita T; Uchida Y; Kuriyama S
Hepatogastroenterology; 2005; 52(62):471-4. PubMed ID: 15816460
[TBL] [Abstract][Full Text] [Related]
28. LC-MS/MS method for the quantification of aldose reductase inhibitor-epalrestat and application to pharmacokinetic study.
Nirogi R; Kandikere V; Ajjala DR; Bhyrapuneni G; Muddana NR
J Pharm Biomed Anal; 2013 Feb; 74():227-34. PubMed ID: 23245255
[TBL] [Abstract][Full Text] [Related]
29. The effects of zenarestat, an aldose reductase inhibitor, on peripheral neuropathy in Zucker diabetic fatty rats.
Shimoshige Y; Ikuma K; Yamamoto T; Takakura S; Kawamura I; Seki J; Mutoh S; Goto T
Metabolism; 2000 Nov; 49(11):1395-9. PubMed ID: 11092500
[TBL] [Abstract][Full Text] [Related]
30. Epalrestat improves diabetic wound healing via increased expression of nerve growth factor.
Nakagaki O; Miyoshi H; Sawada T; Atsumi T; Kondo T; Atsumi T
Exp Clin Endocrinol Diabetes; 2013 Feb; 121(2):84-9. PubMed ID: 23426701
[TBL] [Abstract][Full Text] [Related]
31. Cardiac sympathetic neuropathy and effects of aldose reductase inhibitor in streptozotocin-induced diabetic rats.
Kurata C; Okayama K; Wakabayashi Y; Shouda S; Mikami T; Tawarahara K; Sugiyama T
J Nucl Med; 1997 Nov; 38(11):1677-80. PubMed ID: 9374332
[TBL] [Abstract][Full Text] [Related]
32. Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics.
Misawa S; Kuwabara S; Kanai K; Tamura N; Nakata M; Sawai S; Yagui K; Hattori T
Neurology; 2006 May; 66(10):1545-9. PubMed ID: 16717216
[TBL] [Abstract][Full Text] [Related]
33. Aldose reductase inhibitor, epalrestat, reduces lipid hydroperoxides in type 2 diabetes.
Ohmura C; Watada H; Azuma K; Shimizu T; Kanazawa A; Ikeda F; Yoshihara T; Fujitani Y; Hirose T; Tanaka Y; Kawamori R
Endocr J; 2009; 56(1):149-56. PubMed ID: 18997444
[TBL] [Abstract][Full Text] [Related]
34. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.
Yoshida T; Nishioka H; Yoshioka K; Nakano K; Kondo M; Terashima H
Diabetes; 1987 Jan; 36(1):6-13. PubMed ID: 3025043
[TBL] [Abstract][Full Text] [Related]
35. Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus.
Ikeda T; Iwata K; Tanaka Y
Diabetes Res Clin Pract; 1999 Mar; 43(3):193-8. PubMed ID: 10369429
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and biological evaluation of new epalrestat analogues as aldose reductase inhibitors (ARIs).
Reddy TN; Ravinder M; Bagul P; Ravikanti K; Bagul C; Nanubolu JB; Srinivas K; Banerjee SK; Rao VJ
Eur J Med Chem; 2014 Jan; 71():53-66. PubMed ID: 24275248
[TBL] [Abstract][Full Text] [Related]
37. Effects of a new aldose reductase inhibitor on various tissues in vitro.
Terashima H; Hama K; Yamamoto R; Tsuboshima M; Kikkawa R; Hatanaka I; Shigeta Y
J Pharmacol Exp Ther; 1984 Apr; 229(1):226-30. PubMed ID: 6423811
[TBL] [Abstract][Full Text] [Related]
38. A placebo-controlled double-blind study of epalrestat (ONO-2235) in patients with diabetic neuropathy.
Goto Y; Hotta N; Shigeta Y; Sakamoto N; Kito S; Matsuoka K; Takahashi A; Kikkawa R; Sakuma A
Diabet Med; 1993; 10 Suppl 2():39S-43S. PubMed ID: 8334840
[No Abstract] [Full Text] [Related]
39. Alpha lipoic acid combined with epalrestat: a therapeutic option for patients with diabetic peripheral neuropathy.
Wang X; Lin H; Xu S; Jin Y; Zhang R
Drug Des Devel Ther; 2018; 12():2827-2840. PubMed ID: 30233145
[TBL] [Abstract][Full Text] [Related]
40. A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report.
Valensi P; Le Devehat C; Richard JL; Farez C; Khodabandehlou T; Rosenbloom RA; LeFante C
J Diabetes Complications; 2005; 19(5):247-53. PubMed ID: 16112498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
